FLAZIFINE

Flazifin



Trade name of the drug: Flazifin

Active ingredient (INN): Fructose-1, 6 – diphosphate trisodium salt.

Dosage form: powder for the preparation of solution for infusion.

Composition: each bottle of powder contains: Fructose-1,6-diphosphate trisodium salt (in the form of fructose-1, 6 - diphosphate trisodium octahydrate) 5 g.
Each bottle of solvent contains: Water for injection 50 ml.

Description: white or almost white

Pharmacotherapeutic group: Cardiovascular drugs.

ATC code: CO1EB07.

Pharmacological properties: the main mechanism of action of the drug is associated with the cell wall. FDF stimulates the activity of phosphofructokinase, 
pyruvate kinase and lactate kinase, which leads to an increase in intracellular high-energy phosphate. Also, interaction with the 
cell surface leads to accelerated diffusion of potassium ions into the cell.

It has been established that Flazifin protects red blood cells from hemolysis and prevents the formation of toxic oxygen radicals.

Flazifin prevents a decrease in ATP in the heart muscle, prevents the negative consequences of hypokalemia and ensures cardiac activity.

Flazifin provides the energy reserve of the myocardium during coronary heart disease, protects the liver and kidneys from ischemia, and plays an important role

in restoring blood circulation in hemorrhagic and traumatic shock.


Clinical trials show that with repeated blood transfusions, Flazifin increases the intraerythrocyte energy reserve,
reduces the concentration of potassium in the transfused plasma, restores the normal sodium-potassium ratio inside the cells, 
increases the elasticity and hemolytic resistance of erythrocytes, normalizes nitrogen metabolism during parenteral nutrition,
acute myocardial infarction improves hemodynamics in patients with heart attacks and peripheral vascular diseases.

Indications:

Acute myocardial infarction, shock.
Chronic heart failure.
Myocardial infarction during surgery.
Various localized ischemia, including severe ischemia of the lower extremities.
Hypophosphatemia due to metabolic disorders.
IHD (unstable angina, myocardial infarction and their complications).
Acute left ventricular failure (pulmonary edema).

Contraindications: hypersensitivity to the drug, hyperphosphatemia, renal failure.

Special instructions and precautions:

If Flazifin gets into the subcutaneous tissue during injection, it causes pain and irritation.

For young children, the drug is prescribed only if necessary under the strict supervision of a doctor.

Blood phosphate levels in patients with creatinine clearance below 50 ml/min should be constantly monitored.

Interaction with other drugs:

Interactions of Flazifin with other drugs have not been recorded.
Flazifin should not be mixed with drugs that are insoluble at pH 5.5 and alkaline solutions of calcium salts.

Use during pregnancy and lactation:

No adverse events were recorded in women who used the drug in the 3rd month of pregnancy.

Directions for use and dosage:

Flazifin is administered only intravenously by drip method (at a rate of about 1 g/min). 5 g of flazifin is dissolved in 
50 ml of solvent to obtain a 10% solution. For rapid intravenous administration (approximately 1 g/min, corresponding to 10 ml/min), 
Flazifin is mixed with 50 ml of solvent to obtain a 10% solution

The daily dose and duration of treatment are determined by the severity of the disease. In acute situations, the drug is usually prescribed
at a dose of 125–175 mg/kg body weight (2 ampoules per day), maximum dose - 250 mg/kg. If necessary, use a higher
The total daily dose should be set to 2 times. In chronic cases, the dose taken is 75-160 mg/kg body weight (1-2 ampoules per day).
In case of myocardial ischemia during surgery, the drug is added to the solution for cardioplegia.
For preventive purposes 3-5 days before and 1-2 days after surgery
Prescribe 1 ampoule per day. 1 g of flazifin provides 4.6-4.8 mmol of inorganic phosphate.

Side effects:

No additional effects were identified. Flazifin is usually well tolerated by the body.

Rarely, allergic reactions, hyperphosphatemia, pain at the injection site, thrombosis, phlebitis, and skin irritation are possible.

Release form:

5 g of powder for the preparation of a solution for intravenous infusion in bottles made of 
colorless glass type P. The bottles are closed with bromobutyl rubber coated with an aluminum layer, with a plastic chlorophylline cap.
1 bottle of the drug and 1 bottle of solvent are packed in a cardboard box with an insert.